Glioblastoma, often called GBM, is the most aggressive and common type of primary brain cancer in adults. It grows quickly, spreads into nearby brain tissue, and is difficult to treat. While there is no cure, treatment focuses on slowing tumor growth, managing symptoms, and extending quality of life. Understanding what GBM is, how it presents, and what treatment looks like can help patients and families prepare for the road ahead.
What Is a GBM Glioblastoma?
Glioblastoma is a grade 4 glioma, meaning it is the most malignant form of brain tumor. It arises from astrocytes, the star-shaped cells that support nerve cells in the brain. The tumor is highly invasive, meaning it sends tentacle-like projections into surrounding healthy brain tissue. This makes complete surgical removal impossible.
GBM is classified as either primary or secondary. Primary glioblastoma develops quickly and without warning, often in older adults. Secondary glioblastoma progresses slowly from a lower-grade tumor over several years, usually in younger patients. Both types share the same aggressive behavior once they reach grade 4.
The exact cause of glioblastoma is unknown. Most cases occur sporadically, with no clear risk factor. Exposure to high doses of ionizing radiation is the only established environmental risk factor. Family history plays a role in a very small percentage of cases.
What Are the Symptoms of Glioblastoma?
Symptoms depend on the tumor’s location and size. Because GBM grows rapidly, symptoms often appear suddenly and worsen over weeks. Headaches are common, especially ones that are worse in the morning or accompanied by nausea. These headaches result from increased pressure inside the skull.
Seizures are another frequent symptom. They may be the first sign of the tumor in some patients. Seizures occur because the tumor irritates surrounding brain tissue and disrupts normal electrical activity.
Other symptoms include weakness on one side of the body, difficulty speaking, vision changes, confusion, and personality changes. The specific symptoms reflect the part of the brain affected. For example, a tumor near the speech center causes language problems, while one near the motor cortex causes weakness.
New or worsening neurological symptoms warrant immediate medical attention. A doctor will order imaging, typically an MRI with contrast, to look for abnormalities. A biopsy is required to confirm the diagnosis.
How Is Glioblastoma Diagnosed?
Diagnosis begins with a neurological exam and imaging. An MRI with contrast is the standard imaging tool. Glioblastoma typically appears as a ring-enhancing mass with a necrotic center, meaning the middle of the tumor has dead tissue. This appearance is characteristic, but not definitive.
Definitive diagnosis requires a biopsy. A neurosurgeon removes a small sample of tumor tissue during surgery. A pathologist examines the tissue under a microscope to confirm the diagnosis and grade. Molecular testing is also performed on the sample.
Two molecular markers matter significantly in glioblastoma: MGMT promoter methylation and IDH mutation status. MGMT methylation predicts better response to chemotherapy. IDH mutations are more common in secondary glioblastoma and are associated with a slightly better prognosis. These markers help guide treatment decisions and provide prognostic information.
What Is the Standard Treatment for Glioblastoma?
Standard treatment follows a three-part approach: surgery, radiation, and chemotherapy. This combination is called the Stupp protocol, named after the clinical trial that established it. It remains the standard of care for newly diagnosed glioblastoma.
Surgery is the first step. The goal is to remove as much tumor as possible without damaging critical brain functions. This is called maximal safe resection. Complete removal is not possible because tumor cells invade healthy tissue. The amount of tumor removed affects survival, so surgeons aim for the most extensive safe removal possible.
After surgery, patients typically receive radiation therapy. Radiation is given daily over several weeks to the tumor bed and surrounding area. It kills remaining tumor cells that surgery could not remove.
Chemotherapy follows and accompanies radiation. Temozolomide is the standard chemotherapy drug for glioblastoma. It is an oral medication taken daily during radiation, then in cycles afterward. Temozolomide works best in patients with MGMT promoter methylation.
What Are the Treatment Options for Recurrent Glioblastoma?
Most glioblastomas recur despite initial treatment. Recurrence is nearly inevitable because residual tumor cells survive surgery, radiation, and chemotherapy. Treatment at recurrence depends on the patient’s overall health, tumor location, and previous treatments.
Surgery may be considered again if the recurrence is accessible and the patient is healthy enough. Radiation can sometimes be repeated, though this is limited by prior exposure. Chemotherapy options include different dosing schedules of temozolomide or alternative drugs like bevacizumab.
Bevacizumab is a targeted therapy that blocks blood vessel growth to the tumor. It does not cure glioblastoma but can reduce symptoms and improve quality of life by decreasing swelling and tumor size. It is not a first-line treatment but is used in specific situations.
Clinical trials are often available for recurrent glioblastoma. These trials test new drugs, immunotherapies, and treatment combinations. Patients should discuss trial options with their neuro-oncologist. Tumor treating fields, a device that delivers alternating electric fields to the brain, is another option approved for recurrent and newly diagnosed GBM.
What Is the Prognosis for Glioblastoma?
The prognosis for glioblastoma is poor. Median survival is approximately 15 months with standard treatment. About 25% of patients survive two years, and fewer than 10% survive five years. These numbers reflect averages, and individual outcomes vary widely.
Several factors influence prognosis. Younger age at diagnosis is associated with better outcomes. Patients with MGMT promoter methylation respond better to temozolomide and have longer survival. IDH-mutant tumors also carry a better prognosis than IDH-wildtype tumors.
Performance status, meaning how well a patient functions in daily life, also matters. Patients who are physically active and independent at diagnosis tend to do better. The extent of surgical resection is another factor, with more complete removal associated with longer survival.
These statistics are sobering, and honesty about prognosis matters. However, individual responses to treatment vary. Some patients live years beyond the average, and ongoing research continues to improve outcomes.
What Are the Side Effects of Treatment?
Treatment side effects are significant and vary by modality. Surgery carries risks of infection, bleeding, and neurological deficits. Swelling in the brain after surgery is common and managed with steroids.
Radiation therapy causes fatigue, hair loss at the treatment site, and skin irritation. Some patients experience cognitive changes, including memory and concentration problems. These effects can persist after radiation ends.
Temozolomide causes nausea, fatigue, constipation, and lowered blood cell counts. Low blood counts increase infection risk and may require dose adjustments. Most side effects are manageable with supportive medications.
Steroids, particularly dexamethasone, are commonly used to reduce brain swelling. They cause weight gain, insomnia, elevated blood sugar, and muscle weakness. Long-term steroid use carries additional risks, so doctors taper the dose as soon as possible.
What Supportive Care Is Available?
Supportive care focuses on managing symptoms and improving quality of life. This is an essential part of glioblastoma treatment from diagnosis onward. It is not a separate phase that begins when treatment stops.
Seizure medications are prescribed if seizures occur. Anticonvulsants are not given preventively to all patients. Blood thinners may be used to prevent blood clots, which are common in brain tumor patients.
Physical, occupational, and speech therapy help patients maintain function. These therapies address weakness, coordination, communication, and daily living skills. Palliative care specialists can help manage pain, fatigue, and emotional distress.
Psychological support benefits both patients and caregivers. A glioblastoma diagnosis carries profound emotional weight. Counseling, support groups, and psychiatric care are valuable resources. Caregivers often need support too, as the demands of caregiving are substantial.
Frequently Asked Questions
Is glioblastoma always fatal?
Glioblastoma is not curable with current treatments, and most patients eventually die from the disease. However, a small percentage of patients survive five years or longer, and treatment can extend life and improve quality of time.
How fast does glioblastoma grow?
Glioblastoma is a fast-growing tumor, and symptoms often appear within weeks. The doubling time of the tumor is estimated to be around three weeks, though this varies by individual.
Can glioblastoma be detected on a CT scan?
A CT scan can show a mass and signs of swelling, but MRI with contrast is the preferred imaging method. MRI provides clearer detail of the tumor’s extent and characteristics, which helps guide surgery.
What is the newest treatment for glioblastoma?
Tumor treating fields is a newer FDA-approved treatment that uses electric fields to disrupt tumor cell division. It extends survival when used with chemotherapy after radiation, though it requires wearing a device on the scalp for most of the day.
